Regeneron Pharmaceuticals catalysts could drive stock higher: analysts

JP Morgan analysts issued an 'Overweight' rating on Regeneron Pharmaceuticals (REGN) with an $800 year-end price target, citing an attractive setup driven by its Dupixent and Eylea franchises and several anticipated catalysts. These catalysts, expected within 3-6 months, include Phase 3 LAG3 melanoma trial results and Eylea updates, alongside accelerating 8mg Eylea uptake and Dupixent's continued growth in core indications and new launches like COPD. The firm projects Q3 2025 sales of $3.6 billion and EPS of $9.25, slightly above Wall Street estimates, which contributed to a more than 1% rise in REGN shares in early trading.

Analysis

JP Morgan has issued a bullish outlook on Regeneron Pharmaceuticals (REGN) with an 'Overweight' rating and an $800 year-end price target, suggesting substantial upside from the stock's early trading price of $606.50. The core of the thesis is that the company's valuation is fully supported by its two key drugs, Dupixent and Eylea, along with its cash reserves, implying that any positive developments from the pipeline are not yet priced in. The firm identifies several potential catalysts within the next three to six months, including Phase 3 trial results for its LAG3 melanoma treatment and multiple updates for Eylea. Growth is expected to be driven by an accelerating uptake of the 8mg Eylea formulation, pending label enhancements, and continued expansion of Dupixent in core indications like atopic dermatitis and asthma, plus new launches for conditions such as COPD. Reflecting this optimism, JP Morgan's forecast for Q3 2025 sales is $3.6 billion with earnings per share of $9.25, both slightly exceeding Wall Street consensus estimates.

Key Decisions for Investors

• Investors could view Regeneron as having a favorable risk/reward profile, as the analyst note suggests the current valuation provides a floor based on existing commercial assets, with pipeline developments offering potential upside.
• Closely monitor the news flow over the next 3-6 months for specific catalysts, particularly the Phase 3 LAG3 data and Eylea label updates, as these are identified as key drivers for a potential stock re-rating.
• Pay close attention to the upcoming Q3 2025 earnings report to see if Dupixent's performance and overall financial results meet or beat JP Morgan's above-consensus estimates, which would serve as validation for the bullish thesis.